Navigation Links
Quest Diagnostics Again Named to FORTUNE Magazine's 'World's Most Admired Companies' List

Ranks second overall and first for long-term investment and social responsibility in industry category

MADISON, N.J., March 3 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, has again been named to FORTUNE magazine's list of the World's Most Admired Companies. Quest Diagnostics ranked second in the "Health Care" category of "Pharmacy and Other Services." The 2009 ranking is the second consecutive year that the company has been included on FORTUNE's Most Admired Companies list. The company advanced to second place from third in 2008. The new World's Most Admired Companies list is widely considered the definitive report card on corporate reputations.

"This prestigious recognition reflects the dedicated efforts of our 43,000 employees to put patients first and provide superior diagnostic services," said Surya N. Mohapatra, Ph.D., Chairman and CEO of Quest Diagnostics. "We are particularly gratified to have ranked number one in our industry category for long-term investment, which demonstrates support for our strategy and vision."

FORTUNE's list of the World's Most Admired Companies is based on surveys of more than 4,000 executives, directors and securities analysts of companies they admire most in their industry based on nine criteria: innovation, people management, use of corporate assets, quality of management; social responsibility; financial soundness, long-term investment, quality of products and services, and global competitiveness. For 2009, FORTUNE published one list rather than separate World's Most Admired and America's Most Admired lists in order to better represent the competitive landscape faced by today's companies.

The full list and related stories appear in the March 16 issue of FORTUNE, available on newsstands on Monday, March 9th, and now at:

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at

The statements in this press release that are not historical facts or information may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results and outcomes to be materially different. Certain of these risks and uncertainties may include, but are not limited to, competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors described in the Quest Diagnostics Incorporated 2007 Form 10-K and subsequent SEC filings.

SOURCE Quest Diagnostics Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FRC Action Questions President Obamas Choice of Gov. Sebelius for HHS
2. Presidents 2010 Budget Request Strongly Supports VA Programs
3. An Athletes First Question: Doc, When Can I Return?
4. Six Questions Consumers Should Ask About Genetic Tests
5. Virtual studies answer real questions
6. Findings raise new questions about evolution of hormones in mammals
7. Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire
8. C4CC Education Fund Launches Discussion Forum for Consumers With Health Insurance Questions
9. SurgiQuest Announces FDA Approval for Smoke & Plume Evacuation for AirSeal Dynamic Pressure System(TM)
10. Study questions effectiveness of $80 million per year brain exercise products industry
11. ANA and ISONG Co-Publish Genetics and Ethics in Health Care: New Questions in the Age of Genomic Health
Post Your Comments:
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
Breaking Medicine Technology: